Detection of autoantibodies to multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer

Abstract

We aimed to evaluate the immunodiagnostic values of autoantibodies to a panel of six tumor-associated antigens (TAAs) in the detection of patients with breast cancer. This study determines whether a panel of multiple TAAs would enhance antibody detection and be a useful approach in breast cancer detection and diagnosis. The panel of multiple TAAs was composed of six TAAs including Imp1, p16, Koc, survivin, cyclin B1, and c-myc full-length recombinant proteins. Enzyme-linked immunosorbent assay (ELISA) was used to detect antibodies against these six TAAs in 49 sera from patients with breast cancer, 35 sera from patients with benign breast tumor, and 38 sera from normal individuals. Antibody frequency to any individual TAA in breast cancer was variable and ranged from 12.2 to 18.4%. With the successive addition of TAAs to a final total of six antigens, there was a stepwise increase of positive antibody reactions reaching a sensitivity of 67.3% and a specificity of 92.2% in breast cancer. Positive and negative likelihood ratios were 8.52 and 0.36, respectively, which showed that the clinical diagnostic value of a parallel assay of six TAAs was high. Positive and negative predictive values were, respectively, 91.7 and 68.6%, indicating that the parallel assay of six TAAs raised the diagnostic accuracy greatly. Agreement rate and kappa value were 78.1% and 0.57, respectively, which indicated that the observed value of this assay had a middle range of coincidence with the actual value. The data from this study further support our previous hypothesis that the detection of autoantibodies for diagnosis of a certain type of cancer can be enhanced by using a panel of several carefully selected TAAs as target antigens and a panel of multiple TAAs would be a useful approach in the detection and diagnosis of breast cancer.

Tumour‐Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta‐Analysis

“…After excluding 579 non‐English articles and 1318 duplicates, 4441 articles not relevant to the topic and 58 meeting the exclusion criteria were excluded. Ultimately, 84 articles were included . A total of 196 specific tumour‐associated autoantibodies (Table S1) were reported, of which 23 specific tumour‐associated autoantibodies (Table ) had been studied more than once.…”

“…The 84 articles included participants from 27 countries (Table S1). The most studied populations were Chinese and American , followed by French , German and Italian . The earliest study was from 1982, and anti‐p53 antibody was the first tumour‐associated autoantibody to be reported in patients with BC.…”

“…The 84 articles included participants from 27 countries (Table S1). The most studied populations were Chinese [22,24,28,29,32,40,42,43,49,50,60,65,69,[92][93][94][95][96] and American [11,21,23,38,41,53,58,64,67,71,72,75,81,84], followed by French [4,25,48,52,62,73,74], German [37,55,57,59,80] and Italian [20,34,56,68,79]. The earliest study was from 1982, and anti-p53 antibody was the first tumour-associated autoantibody to be reported in patients ...…”

Autoimmune Response to IGF2 mRNA‐Binding Protein 2 (IMP2/p62) in Breast Cancer

“…It cannot serve as an indicator of early diagnosis of breast cancer. One of our previous studies showed other TAAs (such as Imp1, p16, Koc, survivin, cyclinB1 and c‐myc) had higher autoantibody response in breast cancer . However, diagnosis based on single tumour marker detection of either a TAA or an anti‐TAA antibody usually lacks sensitivity and specificity as noticed in most studies.…”

Tumormarker zur Früherkennung – sinnvoll oder sinnlos?

“…Diese Antikör-per richten sich beispielsweise gegen p53, CEA und RELT (receptor expressed in lymphoid tissues). Sie variieren je nach Tumorentität und aufgrund der Heterogenität der jeweiligen Tumorart auch teilweise innerhalb dieser [16][17][18][19][20]. Die bisherigen Arbeiten an diesem Themenkomplex können bei individuell ermittelten Grenzwerten weitgehend konstant hohe Spezifitäten berichten -bei teilweise sehr niedriger Sensitivität.…”